References
1. Tomasoni D, Italia L, Adamo M, et al. COVID 19 and heart failure:
from infection to
inflammation and angiotensin II stimulation. Searching for evidence from
a new disease
[published online ahead of print, 2020 May 15]. Eur J Heart Fail.
2020;10.1002/ejhf.1871.
doi:10.1002/ejhf.1871
2. Ferrario CM, Jessup J, Chappell MC, et al. Effect of
angiotensin-converting enzyme
inhibition and angiotensin II receptor blockers on cardiac
angiotensin-converting enzyme 2.
Circulation.
2005;111(20):2605‐2610.doi:10.1161/CIRCULATIONAHA.104.510461
3. Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2
Infections in Engineered
Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell.
2020;181(4):905‐913.e7.
doi:10.1016/j.cell.2020.04.004
4. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and
endotheliitis in COVID-
19. Lancet. 2020;395(10234):1417‐1418. doi:10.1016/S0140-6736(20)30937-5
5. Axtell AL, Gomari FA, Cooke JP. Assessing endothelial vasodilator
function with the Endo-
PAT 2000. J Vis Exp. 2010;(44):2167. Published 2010 Oct 15.
doi:10.3791/2167
6. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular
Endothelialitis,
Thrombosis, and Angiogenesis in Covid-19 [published online ahead of
print, 2020 May 21]. N
Engl J Med. 2020;10.1056/NEJMoa2015432. doi:10.1056/NEJMoa2015432